Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1955 1
1957 1
1959 1
1964 1
1966 1
1967 3
1968 3
1969 5
1970 6
1971 8
1972 5
1973 3
1974 12
1975 4
1976 4
1977 5
1978 1
1979 4
1980 6
1981 3
1982 5
1983 2
1984 4
1985 6
1986 5
1987 3
1988 6
1989 7
1990 7
1991 4
1992 4
1993 10
1994 6
1995 7
1996 14
1997 9
1998 8
1999 10
2000 10
2001 8
2002 10
2003 12
2004 19
2005 12
2006 24
2007 24
2008 20
2009 13
2010 25
2011 32
2012 40
2013 47
2014 47
2015 48
2016 55
2017 54
2018 53
2019 64
2020 70
2021 41
2022 32
2023 24
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

893 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Digestive system neuroendocrine neoplasm"
Page 1
Pancreatic neuroendocrine tumors: A review of serum biomarkers, staging, and management.
Ma ZY, Gong YF, Zhuang HK, Zhou ZX, Huang SZ, Zou YP, Huang BW, Sun ZH, Zhang CZ, Tang YQ, Hou BH. Ma ZY, et al. World J Gastroenterol. 2020 May 21;26(19):2305-2322. doi: 10.3748/wjg.v26.i19.2305. World J Gastroenterol. 2020. PMID: 32476795 Free PMC article. Review.
Pancreatic neuroendocrine tumors (pNETs) are a heterogeneous group of tumors with complicated treatment options that depend on pathological grading, clinical staging, and presence of symptoms related to hormonal secretion. ...But other new biomarker mo …
Pancreatic neuroendocrine tumors (pNETs) are a heterogeneous group of tumors with complicated treatment options that de …
Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System: The TOPIC-NEC Phase 3 Randomized Clinical Trial.
Morizane C, Machida N, Honma Y, Okusaka T, Boku N, Kato K, Nomura S, Hiraoka N, Sekine S, Taniguchi H, Okano N, Yamaguchi K, Sato T, Ikeda M, Mizuno N, Ozaka M, Kataoka T, Ueno M, Kitagawa Y, Terashima M, Furuse J; Japan Clinical Oncology Group (JCOG). Morizane C, et al. JAMA Oncol. 2022 Oct 1;8(10):1447-1455. doi: 10.1001/jamaoncol.2022.3395. JAMA Oncol. 2022. PMID: 35980649 Free PMC article. Clinical Trial.
IMPORTANCE: Etoposide plus cisplatin (EP) and irinotecan plus cisplatin (IP) are commonly used as community standard regimens for advanced neuroendocrine carcinoma (NEC). OBJECTIVE: To identify whether EP or IP is a more effective regimen in terms of overall survival (OS) …
IMPORTANCE: Etoposide plus cisplatin (EP) and irinotecan plus cisplatin (IP) are commonly used as community standard regimens for advanced …
(177)Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.
Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, Mittra E, Wolin EM, Yao JC, Pavel ME, Grande E, Van Cutsem E, Seregni E, Duarte H, Gericke G, Bartalotta A, Mariani MF, Demange A, Mutevelic S, Krenning EP; NETTER-1 investigators. Strosberg JR, et al. Lancet Oncol. 2021 Dec;22(12):1752-1763. doi: 10.1016/S1470-2045(21)00572-6. Epub 2021 Nov 15. Lancet Oncol. 2021. PMID: 34793718 Clinical Trial.
Here, we report the prespecified final analysis of overall survival and long-term safety results. METHODS: This open-label, randomised, phase 3 trial enrolled patients from 41 sites in eight countries across Europe and the USA. ...This trial is registered wit …
Here, we report the prespecified final analysis of overall survival and long-term safety results. METHODS: This open-label, randomised …
Claudin-18.
Wong MT, Singhi AD, Larson BK, Huynh CAT, Balzer BL, Burch M, Dhall D, Gangi A, Gong J, Guindi M, Hendifar AE, Kim SA, de Peralta-Venturina M, Waters KM. Wong MT, et al. Arch Pathol Lab Med. 2022 May 1;147(5):559-567. doi: 10.5858/arpa.2021-0428-OA. Arch Pathol Lab Med. 2022. PMID: 35976638 Free article.
Additionally, gastric (n = 40) and nongastric (n = 322) neuroendocrine tumors were included. Claudin-18 expression was evaluated for any staining as positive and by meeting clinical trial inclusion criteria (2+ intensity in 50% of tumor). ...Claudin-18 …
Additionally, gastric (n = 40) and nongastric (n = 322) neuroendocrine tumors were included. Claudin-18 expression was evaluat …
EUS-guided intra-tumoral therapies.
Marc B, Monino L, Rimbas M. Marc B, et al. Best Pract Res Clin Gastroenterol. 2022 Sep-Dec;60-61:101817. doi: 10.1016/j.bpg.2022.101817. Epub 2022 Dec 14. Best Pract Res Clin Gastroenterol. 2022. PMID: 36577536
The lesions detected include mostly pancreatic cystic neoplasms (PCN) and neuroendocrine tumors (NET) mainly well differentiated. Clinically, NET are mostly non-functional and do not induce secretory disorders [5-8]. ...EUS-guided treatment for pancreatic adenocarci …
The lesions detected include mostly pancreatic cystic neoplasms (PCN) and neuroendocrine tumors (NET) mainly well differentiat …
Neuroendocrine Tumors.
Basuroy R, Srirajaskanthan R, Ramage JK. Basuroy R, et al. Gastroenterol Clin North Am. 2016 Sep;45(3):487-507. doi: 10.1016/j.gtc.2016.04.007. Gastroenterol Clin North Am. 2016. PMID: 27546845 Review.
Neuroendocrine tumors are increasingly diagnosed, either incidentally as part of screening processes, or for symptoms, which have commonly been mistaken for other disorders initially. ...
Neuroendocrine tumors are increasingly diagnosed, either incidentally as part of screening processes, or for symptoms, which h …
Progress in immunotherapy for neuroendocrine neoplasm of the digestive system.
Pan WX, Zhang XM, Hao SL, Han W. Pan WX, et al. World J Gastroenterol. 2023 Jul 14;29(26):4174-4185. doi: 10.3748/wjg.v29.i26.4174. World J Gastroenterol. 2023. PMID: 37475845 Free PMC article. Review.
Neuroendocrine neoplasms (NENs) are rare heterogeneous tumors that can develop in almost any organ, with the digestive organs, including the gastrointestinal tract and pancreas being the most commonly affected sites. ...Therefore, the purpose of this review i …
Neuroendocrine neoplasms (NENs) are rare heterogeneous tumors that can develop in almost any organ, with the digestive …
Radionuclide Therapy for Neuroendocrine Tumors.
Cives M, Strosberg J. Cives M, et al. Curr Oncol Rep. 2017 Feb;19(2):9. doi: 10.1007/s11912-017-0567-8. Curr Oncol Rep. 2017. PMID: 28220446 Review.
The two radiopeptides most commonly used for PRRT, (90)Y-DOTATOC and (177)Lu-DOTATATE, have been successfully employed for more than a decade for the treatment of advanced neuroendocrine tumors (NETs). Recently, the phase III, randomized NETTER-1 trial …
The two radiopeptides most commonly used for PRRT, (90)Y-DOTATOC and (177)Lu-DOTATATE, have been successfully employed for more than a decad …
Digestive neuroendocrine neoplasms: A 2016 overview.
Merola E, Rinzivillo M, Cicchese N, Capurso G, Panzuto F, Delle Fave G. Merola E, et al. Dig Liver Dis. 2016 Aug;48(8):829-35. doi: 10.1016/j.dld.2016.04.008. Epub 2016 Apr 30. Dig Liver Dis. 2016. PMID: 27212431 Review.
Digestive neuroendocrine neoplasms (DNENs) have an incidence of 2.39 per 100,000 inhabitants per year, and a prevalence of 35 cases per 100,000; the gap between these rates is to be referred to the relatively long survival that characterizes the majority of these …
Digestive neuroendocrine neoplasms (DNENs) have an incidence of 2.39 per 100,000 inhabitants per year, and a prevalence of 35 …
Old and New Gut Hormone, Gastrin and Acid Suppressive Therapy.
Haruma K, Kamada T, Manabe N, Suehiro M, Kawamoto H, Shiotani A. Haruma K, et al. Digestion. 2018;97(4):340-344. doi: 10.1159/000485734. Epub 2018 Mar 27. Digestion. 2018. PMID: 29587283 Review.
As acid suppressive therapy causes hypergastrinemia, the association between acid suppressive therapy and gastric neuroendocrine cell tumor (NET) has been discussed during the past 30 years. ...
As acid suppressive therapy causes hypergastrinemia, the association between acid suppressive therapy and gastric neuroendocrine cell …
893 results